A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: Final report of an Australian multi-centre trial

Radiotherapy and Oncology

Volumn 52, Issue 2, 1999, Pages 129-136

  Ball, David ^a   Bishop, James ^a   Smith, Jennifer ^a   O'Brien, Peter ^b   Davis, Sidney ^a   Ryan, Gail ^a   Olver, Ian ^c   Toner, Guy ^a   Walker, Quenten ^d   Joseph, David ^e  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b Mater Misericordiae Hospital   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^e GEELONG HOSPITAL   (Australia)

Author keywords

Accelerated fractionation; Carboplatin; Non small cell lung cancer; Radiotherapy

Indexed keywords

CARBOPLATIN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INOPERABLE CANCER; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION SICKNESS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DOSE FRACTIONATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIOTHERAPY; SURVIVAL RATE;

EID: 0033179880     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(99)00093-6     Document Type: Article

References (18)

1. Ball D., Bishop J., Smith J., et al. A phase III study of accelerated radiotherapy with and without carboplatin in nonsmall cell lung cancer: an interim toxicity analysis of the first 100 patients. Int. J. Radiat. Oncol. Biol. Phys. 31:1995;267-272.
2. Ball D., Matthews J., Worotniuk V., Crennan E. Longer survival with higher doses of thoracic radiotherapy in patients with limited non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 25:1993;599-604.
3. Begg A.C., van der Kolk P.J., Emondt J., Bartelink H. Radiosensitization in vitro by cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II) (carboplatin, JM8) and ethylenediammine-malonatoplatinum(II) (JM40). Radiother. Oncol. 9:1987;157-165.
4. Clamon G., Herndon J., Cooper R., Chang A.Y., Rosenman J., Green M.R. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J. Clin. Oncol. 17:1999;4-11.
5. Dillman R.O., Seagren S.L., Propert K.J., et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N. Engl. J. Med. 323:1990;940-945.
6. Groen H.J.M., Sleijfer S., Meijer C., et al. Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines. Br. J. Cancer. 72:1995;1406-1411.
7. Hermanek P., Sobin L.H. TNM Classification of malignant tumours. 4 :1987;Springer, Berlin.
8. Jeremic B., Shibamoto Y., Acimovic L., Djuric L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J. Clin. Oncol. 13:1995;452-458.
9. Jeremic B., Shibamoto Y., Acimovic L., Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J. Clin. Oncol. 14:1996;1065-1070.
10. Kalbfleisch J.D., Prentice R.L. The statistical analysis of failure time data. 1980;John Wiley & Sons, New York.
11. Komaki R., Scott C.B., Sause W.T., et al. Induction cisplatin/vinblastine and irradiation vs irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Int. J. Radiat. Oncol. Biol. Phys. 39:1997;537-544.
12. Mehta C., Patel N. StatXact 4 for Windows. 1998;Cytel Software Corporation, Cambridge, MA.
13. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
14. Millward M., Porceddu S., Ball D., et al. Combined modality treatment using concurrent radiotherapy and pharmacologically guided carboplatin for non-small cell lung cancer (abstr.). Lung Cancer. 18:(Suppl. 1):1997;134.
15. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br. Med. J. 311:1995;899-909.
16. Saunders M., Dische S., Barrett A., Harvey A., Gibson D., Parmar M. (On behalf of the CHART Steering Committee) Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. Lancet. 350:1997;161-165.
17. Schaake-Koning C., van den Bogaert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N. Engl. J. Med. 326:1992;524-530.
18. S-plus 4.0.3. Seattle, WA: Data Analysis Products Division, MathSoft, 1997.